SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Joe Frazier — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJoe Frazier
Date of birth1944-01-12
IdentifiersMRN HR-BX004-SYN-TD; SSN (made up) 000-04-5590
Document date2008-04-13
AuthorClarence Whitfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Eight-week review: blood pressure, lipids, kidney function, semaglutide and the endoscopy result. [S]

History of Present Illness

Mr. Frazier returns six weeks after the consultation. He took semaglutide 0.25 mg weekly for four weeks and has taken 0.5 mg for two weeks; he had mild nausea for two days after each step and none now, and no abdominal pain. His appetite is smaller and he has lost 1.8 kg. He takes amlodipine 5 mg; home readings average 136/84. He has had no alcohol. The upper endoscopy last week showed no varices. He attended the first diabetes class. His eye appointment is next month. [S]

ElementDetail
Semaglutide0.25 mg for four weeks, 0.5 mg for two weeks; mild nausea after each step, now gone
Home blood pressureAverage 136/84 on amlodipine 5 mg
EndoscopyNo varices
AlcoholNone

Review of Systems

SystemResultFinding
GastrointestinalNegativeNausea after each dose step, now gone; no abdominal pain, vomiting or black stools
CardiovascularNegativeNo ankle swelling or chest pain
MusculoskeletalNegativeNo muscle aches

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for yearsOne tablet twice daily with mealsOral route2008-02-16activeS
Lisinopril 20 mg oral tablet, one tablet daily; taken for yearsOne tablet dailyOral route2008-02-16activeS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route2008-02-16activeS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2008-03-02 to 2008-04-13completedS
Amlodipine 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2008-04-13activeS
Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly0.25 mg weekly for four weeks, then 0.5 mg weeklySubcutaneous route2008-03-02 to 2008-05-18completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2008-04-13Body height182cmS
2008-04-13Body weight101.8kgS
2008-04-13Body mass index (BMI) [Ratio]30.7kg/m2S
2008-04-13Systolic blood pressure134mm[Hg]S
2008-04-13Diastolic blood pressure82mm[Hg]S
2008-04-13Heart rate72/minS
2008-04-13Respiratory rate16/minS
2008-04-13Body temperature36.7CelS
2008-04-13Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2008-04-13Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
2008-04-13Creatinine [Mass/volume] in Serum or Plasma1.1mg/dL0.74-1.35 mg/dLNormalS
2008-04-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2003)/1.73 sq M75mL/min/{1.73_m2}60 or higher without kidney damage markers is not CKDNormalS
2008-04-13Cholesterol [Mass/volume] in Serum or Plasma148mg/dL<=199 mg/dLNormalS
2008-04-13Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation68mg/dLGoal below 70 mg/dL with diabetes and other risk factorsNormalS
2008-04-13Cholesterol in HDL [Mass/volume] in Serum or Plasma40mg/dL>=40 mg/dLNormalS
2008-04-13Triglyceride [Mass/volume] in Serum or Plasma168mg/dL<=149 mg/dLHighS
2008-04-13Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma44U/L10-40 U/LHighS
2008-04-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma40U/L7-55 U/LNormalS

Physical Exam

Vital signs recorded on 2008-04-13; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 134/82, pulse 72; weight 101.8 kg
CardiovascularNo ankle edema
AbdomenSoft and non-tender; no ascites

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetesactiveconfirmed E11.65S — Synthetic modern diagnosis; diabetes was reported publicly during his life, but its duration and treatment here are synthetic.
Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressureactiveconfirmed I10S — Synthetic modern diagnosis; high blood pressure was reported publicly during his life.
Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluatedresolvedconfirmed R74.01S — Synthetic presenting finding, superseded at the two-week visit by the elastography and ultrasound diagnosis.
Metabolic dysfunction-associated steatotic liver disease (MASLD): steatosis on elastography (controlled attenuation parameter 318 dB/m) and ultrasound, with diabetes, obesity, low HDL and high triglycerides, and little alcoholactiveconfirmed K76.0S — Synthetic modern diagnosis. Not part of the public record of his life; chosen to teach surveillance.
Compensated cirrhosis (compensated advanced chronic liver disease) from MASLD: liver stiffness 17.6 kPa, platelets 138, nodular liver surface and a spleen of 13.4 cm on ultrasound; no ascites, encephalopathy, bleeding or jaundice; Child-Pugh Aactiveconfirmed K74.69S — Synthetic modern diagnosis. Not part of the public record of his life; the liver cancer diagnosed three years later in the true frame does not appear in the modern episode.
Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statinactiveconfirmed E78.5S — Synthetic laboratory finding.
Obesity, class 1 (BMI 31.4)activeconfirmed E66.811S — Synthetic finding; described without stigma.
Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30activeconfirmed H54.62S — Synthetic modern measurement anchored to the documented cataract in his left eye.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure (clinic and home), weight and BMIEvery visitCompleted today134/82 in the clinic; home average 136/84; weight 101.8 kg
LaboratoryPotassium, creatinine and eGFR (CKD-EPI 2003) on lisinoprilEvery 6 months on an ACE inhibitor, and after changesCompleted todayPotassium 4.7, creatinine 1.10 mg/dL, eGFR 75
LaboratoryLipid panel4 to 12 weeks after starting a statin, then yearlyCompleted todayTotal 148, LDL 68, HDL 40, triglycerides 168 mg/dL
LaboratoryLiver tests with FIB-4With statin start and yearlyCompleted todayAST 44, ALT 40 U/L
LaboratoryHemoglobin A1cEvery 3 months until at goal or after a change in treatment, then every 6 monthsDueDue at three months, in five weeks
Medication safetySemaglutide dose steps, nausea, abdominal pain, gallbladder and pancreatitis symptomsAt each dose stepCompleted today0.5 mg weekly; transient nausea; no abdominal pain
Medication safetyLow blood sugar review and medicine tolerabilityEvery visitCompleted todayNo low blood sugar
ReferralVariceal screeningEndoscopy when portal hypertension cannot be ruled out; repeat in 2 years if no varices and the liver injury continuesCompleted todayEndoscopy last week: no varices; repeat in two years
ImagingLiver ultrasound with AFP for hepatocellular carcinoma surveillanceEvery 6 months in cirrhosisUp to dateBaseline in March; next in September
ExaminationDilated eye examinationAt the start of care, then every 1 to 2 years; promptly when A1c is falling quickly on a GLP-1 receptor agonistOrderedEye clinic appointment next month
Self-managementAlcohol abstinenceEvery visitCompleted todayNo alcohol
Self-managementDiabetes self-management educationAt the start of care and yearlyCompleted todayFirst class attended
Self-managementVaccines for diabetes and chronic liver diseaseAt diagnosis of chronic liver diseaseCompleted todayHepatitis B dose 2 today; hepatitis A dose 2 in September

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]

Guideline basis: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023); Baveno VII - Renewing consensus in portal hypertension (2022); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026)

Follow-up: Three-month review in five weeks with the A1c and home readings. Eye clinic next month. Next scheduled visit 2008-05-18: three-month review: A1c, blood pressure, weight, semaglutide dose and the eye examination. [S]